Liraglutide dosage protocol

What the compound is

Liraglutide (NN2211) is a glucagon-like peptide-1 (GLP-1) analog. It is marketed for the treatment of type 2 diabetes (T2DM) and is also known to reduce body weight (PMID 25202980).

How it is thought to work

Liraglutide's weight loss effect is mediated by binding to GLP-1 receptors (GLP-1Rs) on neurons within the arcuate nucleus (ARC) and other hypothalamic regions in mice. It stimulates proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) neurons and indirectly inhibits neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) (PMID 25202980). In humans, liraglutide (3 mg) delays gastric emptying and increases satiation (PMID 35894080).

For type 2 diabetes-associated non-alcoholic fatty liver disease (NAFLD), liraglutide improved glucose metabolism and liver tissue damage in mice by regulating lipid metabolism related signaling, including AMPK and ACC. It also inhibited ferroptosis in liver cells (PMID 37770820). In diabetic mouse models, liraglutide promoted wound healing by improving re-epithelialization, collagen deposition, and extracellular matrix remodeling. This occurs by stabilizing Myo1c and enhancing its interaction with Dock5, promoting keratinocyte proliferation, migration, and adhesion (PMID 39159301).

What laboratory and animal studies report

In mice with type 2 diabetes-associated NAFLD, liraglutide improved glucose metabolism and ameliorated liver tissue damage, activating the AMPK/ACC pathway and inhibiting ferroptosis (PMID 37770820). Studies in mice also showed liraglutide directly binds to and activates neurons in the arcuate nucleus, crucial for weight regulation (PMID 25202980). Diabetic mouse models demonstrated that liraglutide accelerates wound closure by enhancing keratinocyte functions (PMID 39159301).

Human evidence so far

In a 56-week clinical trial involving adults with overweight or obesity and type 2 diabetes, liraglutide (3.0 mg daily) led to a 6.0% mean weight loss, compared to 2.0% with placebo. A 1.8 mg dose resulted in a 4.7% weight loss. Over 54% of participants on 3.0 mg liraglutide lost 5% or more of their baseline weight (PMID 26284720).

A separate 16-week placebo-controlled trial in adults with obesity showed that 3 mg liraglutide daily increased weight loss, delayed gastric emptying, and increased fasting gastric volume and satiation (PMID 35894080). In adults with type 1 diabetes, adding liraglutide (1.2 or 1.8 mg) to insulin therapy reduced HbA1c levels, total insulin dose, and body weight. However, it also increased rates of symptomatic hypoglycemia and hyperglycemia with ketosis, limiting its clinical use in this group (PMID 27506222).

Key terms explained

GLP-1 receptor: A protein on cell surfaces that binds to glucagon-like peptide-1, influencing functions like insulin release and appetite.

Ferroptosis: A type of programmed cell death characterized by iron-dependent accumulation of lipid peroxides.

AMPK/ACC pathway: A cellular signaling pathway involved in regulating energy metabolism, including lipid synthesis.